Não é de hoje que Calvinho tem criticado veementemente as reformas processuais ocorridas nas últimas décadas na América ...

No passado Domingo, Braga passou o testemunho a Ponta Delgada como Capital Portuguesa da Cultura (CPC). Um título que ambas as cidades ostentaram, tal como antes Aveiro, enquanto cidades finalistas, ...

Joana Meneses Fernandes realça "o legado que fica" do Braga'25, assegurando que Braga vai continuar a ser uma "capital de ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — ...

The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug. The Wegovy pill, as it’s called, is first oral version of a GLP-1 drug that ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making history again with the first FDA approval of a GLP-1 pill for weight loss.

These two healthcare stocks are top names to invest in, but they haven't both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year. Novo ...

Every chief executive dreams of it: a product so successful that it propels their company from obscurity to superstardom seemingly overnight. Among the lessons from 2025, however, is that runaway ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market. Novo Nordisk has filed a new drug application with the FDA for its ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...

When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company's pipeline candidates will see strong progress in 2026. Novo ...